New registry could save lives from deadliest heart attack complication
NCT ID NCT07470814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will enroll 1,000 patients in China who have a heart attack complicated by cardiogenic shock, a life-threatening condition. Researchers will test a new team-based care system and create a risk model tailored to Chinese patients. The goal is to reduce deaths and improve care across hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a standardized care system that reduces deaths from heart attack complicated by cardiogenic shock in China.
What could go wrong
This is an observational registry study, not a treatment trial. It will collect data but may not directly improve outcomes. Results may not apply outside China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION COMPLICATED WITH CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.